Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 5/20 | 0.61 |
| ▸ | JAK2 | O60674 | 3/20 | 0.56 |
| ▸ | JAK3 | P52333 | 3/20 | 0.56 |
| ▸ | ATR | Q13535 | 2/20 | 0.44 |
| ▸ | ADK | P55263 | 3/20 | 0.41 |
| ▸ | MTOR | P42345 | 6/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 4/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | MOK | Q9UQ07 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3760610 | 1.00 | NOS1 (0.61) | NOS1JAK2JAK3ATRADK | |
| SCHEMBL3765184 | 0.90 | NOS1 (0.64) | NOS1JAK2JAK3ATRADK | |
| SCHEMBL3765436 | 0.89 | NOS1 (0.63) | NOS1JAK2JAK3ATRADK | |
| SCHEMBL3765421 | 0.89 | NOS1 (0.63) | NOS1JAK2JAK3ATRADK | |
| SCHEMBL4458075 | 0.85 | NOS1 (0.64) | NOS1ATRADKMTORPIK3R1 | |
| SCHEMBL4774978 | 0.84 | NOS1 (0.61) | NOS1JAK2JAK3ATRADK | |
| SCHEMBL3770209 | 0.84 | NOS1 (0.71) | NOS1ATRMTORPIK3CAPIK3CG | |
| SCHEMBL3755252 | 0.83 | NOS1 (0.54) | NOS1JAK2JAK3ATRMTOR | |
| SCHEMBL3755254 | 0.83 | NOS1 (0.54) | NOS1JAK2JAK3ATRMTOR | |
| SCHEMBL3752640 | 0.83 | NOS1 (0.64) | NOS1JAK2JAK3ATRADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10144736-B2 | Substituted pteridines useful for the treatment and prevention of viral infections | GILEAD SCIENCES, INC. (US) | 2018-12-04 | — | — | US | claimed |
| US-20100305117-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-12-02 | — | — | US | claimed |
| US-20190152974-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2019-05-23 | — | — | US | disclosed |
| US-10144736-B2 | Substituted pteridines useful for the treatment and prevention of viral infections | GILEAD SCIENCES, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-20100305117-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152974-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | HCCS, DPYD, HAVCR2 | NOS1 2154/4885JAK2 3100/4885JAK3 2753/4885 |
| US-10144736-B2 | Substituted pteridines useful for the treatment and prevention of viral infections | HCCS, DPYD, HAVCR2 | NOS1 2154/4885JAK2 3100/4885JAK3 2753/4885 |
| US-20100305117-A1 | SUBSTITUTED PTERIDINES USEFUL FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | HCCS, DPYD, HAVCR2 | NOS1 2154/4885JAK2 3100/4885JAK3 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.